ID: MRFR/HC/8604-HCR | 90 Pages | Author: Rahul Gotadki | March 2024
Table of Contents
1. EXECUTIVE SUMMARY
1.1. Market Attractiveness Analysis
1.1.1. Hydroxychloroquine market, by Strength
1.1.2. Hydroxychloroquine market, by Application
1.1.3. Hydroxychloroquine market, by Region
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.3. Market Structure
3. RESEARCH METHODOLOGY
3.1. Research Process
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
3.5. Forecast Model
3.6. List of Assumptions
4. MARKET DYNAMICS
4.1. Introduction
4.2. Drivers
4.2.1. Rise in the demand due to COVID-19 epidemic
4.2.2. Favorable regulatory scenario
4.3. Restraints
4.3.1. XXX
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis/Supply Chain Analysis
5.2. Porterβs Five Forces Model
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. Impact Analysis of COVID-19 on Hydroxychloroquine Market
5.3.1. Impact on Supply Chain
5.3.2. Impact on Production
5.3.3. Impact on Pricing
5.3.4. Impact in Major regions (Americas, Europe, Asia-Pacific, Middle East & Africa)
6. HYDROXYCHLOROQUINE MARKET, BY STRENGTH
6.1. Overview
6.2. 200mg
6.3. 400mg
6.4. Others
7. HYDROXYCHLOROQUINE MARKET, BY APPLICATION
7.1. Overview
7.2. Rheumatoid Arthritis
7.3. Malaria
7.4. COVID-19
7.5. Others
8. HYDROXYCHLOROQUINE MARKET, BY REGION
8.1. Overview
8.2. Americas
8.2.1. Market Estimates & Forecast, by Application, 2022β2030
8.2.2. Market Estimates & Forecast, by Strength, 2022β2030
8.2.3. Market Estimates & Forecast, by Region, 2022β2030
8.2.3.1. North America
8.2.3.1.1. Market Estimates & Forecast, by Application, 2022β2030
8.2.3.1.2. Market Estimates & Forecast, by Strength, 2022β2030
8.2.3.1.3. Market Estimates & Forecast, by Country, 2022-2030
8.2.3.1.3.1. US
8.2.3.1.3.1.1. Market Estimates & Forecast, by Application, 2022β2030
8.2.3.1.3.1.2. Market Estimates & Forecast, by Strength, 2022β2030
8.2.3.1.3.2. Canada
8.2.3.1.3.2.1. Market Estimates & Forecast, by Application, 2022β2030
8.2.3.1.3.2.2. Market Estimates & Forecast, by Strength, 2022β2030
8.2.3.2. Latin America
8.2.3.2.1. Market Estimates & Forecast, by Application, 2022β2030
8.2.3.2.2. Market Estimates & Forecast, by Strength, 2022β2030
8.3. Europe
8.3.1. Market Estimates & Forecast, by Application, 2022β2030
8.3.2. Market Estimates & Forecast, by Strength, 2022β2030
8.3.3. Market Estimates & Forecast, by Region, 2022β2030
8.3.3.1. Western Europe
8.3.3.1.1. Market Estimates & Forecast, by Application, 2022β2030
8.3.3.1.2. Market Estimates & Forecast, by Strength, 2022β2030
8.3.3.1.3. Market Estimates & Forecast, by Country, 2022β2030
8.3.3.1.3.1. Germany
8.3.3.1.3.1.1. Market Estimates & Forecast, by Application, 2022β2030
8.3.3.1.3.1.2. Market Estimates & Forecast, by Strength, 2022β2030
8.3.3.1.3.2. France
8.3.3.1.3.2.1. Market Estimates & Forecast, by Application, 2022β2030
8.3.3.1.3.2.2. Market Estimates & Forecast, by Strength, 2022β2030
8.3.3.1.3.3. UK
8.3.3.1.3.3.1. Market Estimates & Forecast, by Application, 2022β2030
8.3.3.1.3.3.2. Market Estimates & Forecast, by Strength, 2022β2030
8.3.3.1.3.4. Italy
8.3.3.1.3.4.1. Market Estimates & Forecast, by Application, 2022β2030
8.3.3.1.3.4.2. Market Estimates & Forecast, by Strength, 2022β2030
8.3.3.1.3.5. Spain
8.3.3.1.3.5.1. Market Estimates & Forecast, by Application, 2022β2030
8.3.3.1.3.5.2. Market Estimates & Forecast, by Strength, 2022β2030
8.3.3.1.3.6. Rest of Western Europe
8.3.3.1.3.6.1. Market Estimates & Forecast, by Application, 2022β2030
8.3.3.1.3.6.2. Market Estimates & Forecast, by Strength, 2022β2030
8.3.3.2. Eastern Europe
8.3.3.2.1. Market Estimates & Forecast, by Application, 2022β2030
8.3.3.2.2. Market Estimates & Forecast, by Strength, 2022β2030
8.4. Asia-Pacific
8.4.1. Market Estimates & Forecast, by Application, 2022β2030
8.4.2. Market Estimates & Forecast, by Strength, 2022β2030
8.4.3. Market Estimates & Forecast, by Country, 2022β2030
8.4.3.1. China
8.4.3.1.1. Market Estimates & Forecast, by Application, 2022β2030
8.4.3.1.2. Market Estimates & Forecast, by Strength, 2022β2030
8.4.3.2. India
8.4.3.2.1. Market Estimates & Forecast, by Application, 2022β2030
8.4.3.2.2. Market Estimates & Forecast, by Strength, 2022β2030
8.4.3.3. Japan
8.4.3.3.1. Market Estimates & Forecast, by Application, 2022β2030
8.4.3.3.2. Market Estimates & Forecast, by Strength, 2022β2030
8.4.3.4. Australia
8.4.3.4.1. Market Estimates & Forecast, by Application, 2022β2030
8.4.3.4.2. Market Estimates & Forecast, by Strength, 2022β2030
8.4.3.5. South Korea
8.4.3.5.1. Market Estimates & Forecast, by Application, 2022β2030
8.4.3.5.2. Market Estimates & Forecast, by Strength, 2022β2030
8.4.3.6. Rest of Asia-Pacific
8.4.3.6.1. Market Estimates & Forecast, by Application, 2022β2030
8.4.3.6.2. Market Estimates & Forecast, by Strength, 2022β2030
8.5. Middle East & Africa
8.5.1. Market Estimates & Forecast, by Application, 2022β2030
8.5.2. Market Estimates & Forecast, by Strength, 2022β2030
8.5.3. Market Estimates & Forecast, by Country, 2022β2030
8.5.3.1. Middle East
8.5.3.1.1. Market Estimates & Forecast, by Application, 2022β2030
8.5.3.1.2. Market Estimates & Forecast, by Strength, 2022β2030
8.5.3.2. Africa
8.5.3.2.1. Market Estimates & Forecast, by Application, 2022β2030
8.5.3.2.2. Market Estimates & Forecast, by Strength, 2022β2030
9. COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Hydroxychloroquine Market
9.5. Competitive Benchmarking
9.6. Leading Player in Terms of Number of Developments in Hydroxychloroquine Market
9.7. Key Developments & Growth Strategies
9.7.1. New Product Launch
9.7.2. Merger & Acquisition
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix
9.8.1. Sales & Operating Income, 2019
9.8.2. Major Players R&D Expenditure, 2019
10. COMPANY PROFILES
10.1. Zydus Cadila
10.1.1. Company Overview
10.1.2. Financial Overview
10.1.3. Product Offered
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Ipca Laboratories
10.3. Sanofi S.A.
10.4. Hikma Pharmaceuticals
10.5. Novartis International AG
10.6. Teva Pharmaceutical Industries Ltd
10.7. Apotex Corporation
10.8. Mylan N.V.
10.9. Concordia Healthcare
10.10. Amneal Pharmaceuticals, Inc.
10.11. Taj Pharmaceuticals
10.12. Sun Pharmaceutical Industries Ltd.
10.13. Shanghai Pharmaceuticals Holding
10.14. Hanlim Pharmaceutical
10.15. Kyung Poong
10.16. Laurus Labs Limited
10.17. Covis Pharmaceuticals, Inc.
10.18. Lupin Pharmaceutical
10.19. Wallace Pharmaceuticals
10.20. Intas Pharmaceuticals
10.21. McW Healthcare
10.22. Macleods Pharmaceuticals
10.23. Cipla
11. APPENDIX
11.1.1. Discussion Blueprint
11.1.2. Related Reports
NOTE:
This table of content is tentative and subject to change as the research progresses.
ο‘ In section 10, only the top 10 companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.
ο‘ Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.
Market Segmentation
Hydroxychloroquine Strength Outlook (USD Billion, 2018-2032)
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Hydroxychloroquine Regional Outlook (USD Billion, 2018-2032)
North America Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
US Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Canada Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Europe Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Germany Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
France Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
UK Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Italy Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Spain Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Rest Of Europe Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Asia-Pacific Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
China Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Japan Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
India Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Australia Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Rest of the World Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Middle East Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Africa Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda
Latin America Outlook (USD Billion, 2018-2032)
Hydroxychloroquine by Strength
200mg
400mg
Others
Hydroxychloroquine Application Outlook (USD Billion, 2018-2032)
Malaria
COVID19
Rheumatoid arthritis
Lupus erythematosus
Q-fever
Porphyria cutnea tarda